23andMe's Fall From $6 Billion To Nearly $0
The once-hot DNA-testing company is struggling to profit. From a report: Five years ago, 23andMe was one of the hottest startups in the world. Millions of people were spitting into its test tubes to learn about their ancestry. Oprah had named its kit one of her favorite things; Lizzo dressed up as one for Halloween; Eddie Murphy name-checked the company on "Saturday Night Live." 23andMe went public in 2021 and its valuation briefly topped $6 billion. Forbes anointed Anne Wojcicki, 23andMe's chief executive and a Silicon Valley celebrity, as the "newest self-made billionaire." Now Wojcicki's self-made billions have vanished. 23andMe's valuation has crashed 98% from its peak and Nasdaq has threatened to delist its sub-$1 stock. Wojcicki reduced staff by a quarter last year through three rounds of layoffs and a subsidiary sale. The company has never made a profit and is burning cash so quickly it could run out by 2025. Silicon Valley's fortunes were built on the lofty ambitions of entrepreneurs swinging for the fences -- even if most of them strike out. Wojcicki, for her part, isn't giving up. She's sticking to her goal to transform 23andMe from a supplier of basic ancestry and health data into a comprehensive healthcare company that develops drugs, offers medical care and sells subscription health reports. She still has to prove the business can sustain itself. She's raised about $1.4 billion for 23andMe, and spent roughly 80% of it. Known for her quirky charm and informal style -- she typically wears workout gear to the office -- Wojcicki, 50, has been searching for fresh capital. But with 23andMe's stock trading at just 74 cents, the company likely can't raise money by selling more shares. And the company's early-stage drug programs are so expensive, she has sought investor partners for some of them, so far unsuccessfully, and given up stakes in others. She could also plug the hole with her own cash. At the center of 23andMe's DNA-testing business are two fundamental challenges. Customers only need to take the test once, and few test-takers get life-altering health results.
Read more of this story at Slashdot.